Glyphic Biotechnologies is decoding the human proteome through full coverage, de novo protein sequencing at single molecule resolutions, advancing beyond the decades old technologies based on mass spectrometry and ELISAs. The Glyphic platform will enable the development of novel therapeutics and diagnostics and, ultimately, a deeper understanding of human biology. The company was founded by Joshua Yang and is built upon research at MIT that established a novel approach to isolate amino acids so that they can be more efficiently sequenced using customized, fluorescent binders and modern readout techniques.